Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "company"

4094 News Found

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
News | August 13, 2025

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY


Apollo Hospitals Q1 FY26 PAT up 42% to Rs. 433 Cr
News | August 13, 2025

Apollo Hospitals Q1 FY26 PAT up 42% to Rs. 433 Cr

Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore


Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
News | August 13, 2025

Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent


Centrient Pharmaceuticals joins UNGC
Sustainability | August 12, 2025

Centrient Pharmaceuticals joins UNGC

Reinforcing commitment to ethical and sustainable growth


Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad
News | August 12, 2025

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

AINU is set to accelerate its expansion footprint, enhance operational capabilities


Sandoz launches renewable energy partnership
Sustainability | August 12, 2025

Sandoz launches renewable energy partnership

The agreement complements other PPAs for Sandoz production sites globally


Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags
Drug Approval | August 12, 2025

Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp


Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial
Drug Approval | August 12, 2025

Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA


Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US
News | August 12, 2025

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline